ONXX Related Analyst Comments
-
Kyprolis Sales On-Track (ONXX) - Jefferies
-
Brean Capital Raises Onyx (ONXX) Price Target to $115
-
Jefferies Lifts PT on Onyx Pharmaceuticals (ONXX) to $104
-
Jefferies Positive on Onyx Pharmaceuticals (ONXX) after NCCN Compendia Listing For Frontline Kyprolis
-
Jefferies Trims PT on Onyx Pharmaceuticals (ONXX) Post Q4
-
Approval of Celgene's (CELG) Pomalyst Largely Expected by Street (ONXX)
-
Onyx Pharma's (ONXX) Kyprolis 'Killin It'
-
Onyx Pharmaceuticals (ONXX) May Have Untapped Opportunity in Frontline Multiple Myeloma
-
Baird Slaps $99 Price Target on Onyx Pharmaceuticals (ONXX)
-
Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); Raising Kyprolis Estimates
-
Onyx's (ONXX) Myeloma Drug Might be used for Earlier Stage Treatments
-
Jefferies Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Predicting Strong Kyprolis Launch
-
Onyx Pharmaceuticals (ONXX) Is Trading at Pre-Kyprolis Approval Levels; Is It Time to Buy?
-
Griffin Securities Reiterates a 'Buy' on Ligand Pharma (LGND); Investors Jumped The Gun...Attractive Opportunity
-
Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); Kyprolis Uptake and Take-out Potential
-
Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); FDA approval of Kyprolis and Increased Takeover Chatter
-
Cantor Fitzgerald Maintains a 'Buy' on Ligand Pharma (LGND); Key Partnered Drug is Approved
-
Deutsche Bank Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); SEARCH Fails, But Success Wasn't Necessary
-
Deutsche Bank Sees $21 of Upside in Onyx (ONXX) Shares If Kyprolis Pricing Inline with Velcade
-
Deutsche Bank Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Expert Weigh In on DECISION
-
Brean Murray Raises PT on Onyx Pharma (ONXX); FDA Grants Regorafenib Priority Review; Takeout Speculation Looms
-
Deutsche Bank Raises Price Target on Onyx Pharmaceuticals (ONXX); Adding M&A Scenario
-
Barclays Raises Price Target on Onyx Pharmaceuticals (ONXX); Kyprolis Gets Surprisingly Supportive Commentary
-
Jefferies Adjusts Estimates and Price Target on Onyx Pharmaceuticals (ONXX); Downside Scenarios Reviewed
-
Goldman Sachs Raises Price Target on Onyx Pharma (ONXX) after FDA Panel Backs CFZ
-
Baird Maintains a 'Neutral' on Onyx Pharmaceuticals (ONXX); Continue Warming Up To Kyprolis
-
Jefferies Said Onyx Pharmaceuticals (ONXX) ASCO Data Confirm Concerns On Carf Regulatory Outlook
-
Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Nexavar Miss Not Real Issue; Kyprolis Remains Focus
-
Barclays Maintains an 'Equalweight' on Onyx Pharmaceuticals (ONXX); Facing Uphill Battle
-
Barclays Maintains an 'Equalweight' on Onyx Pharmaceuticals (ONXX); $4 Upside if MISSION Works
-
Rodman & Renshaw Says Onyx (ONXX) Shares Undervalued; Reiterates Outperform, $57 Price Target
-
Canaccord Genuity Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); Year-end Nexavar Sales Beat
-
Canaccord Genuity on Life Sciences/Biotechnology: Forex Exposure - Impact ITMN, PLX, AEGR & ONXX
-
Canaccord Genuity Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); 2012 Catalyst Highlights
-
Canaccord Biotech Meeting Takeaways Part II: NPSP, ONXX, TSRX, & VICL
-
Goldman Sachs Highlights Best and Worst in Biotech for 2012
-
Short Interest Ticks Up in Large-Cap Biotech, Specifically Amgen (AMGN)
-
Biotech M&A Will Be In Focus in 2012 - Goldman
-
JPMorgan Encouraes Investors to Buy Onyx Pharm. (ONXX) on Dip, Notes CFZ Approval is a Given
-
Canaccord Genuity Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Lowering PT on Expected C-mib Delay
-
Canaccord Genuity on Specialty Pharmaceuticals: Top Catalyst-Driven Stocks with Potential for Upside by Year-End
-
Jefferies Remains Bullish on Onyx Pharmaceuticals (ONXX) Following Encouraging Carfilzomib Data
-
Jefferies Lifts Numbers on Onyx Pharmaceuticals (ONXX)
-
Canaccord Genuity Reiterates a 'Buy' on Onyx Pharmaceuticals (ONXX); Nexavar Margins Improve, Big Catalysts Approach
-
Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Lightning Strikes: Regorafenib CRC Success Adds Meaningfully to Valuation
-
Canaccord Genuity Q3 Biotech Results Preview
-
Onyx (ONXX) Settlement Removes Overhang for Potential Buyers -Stifel Nicolaus
-
Goldman Sachs Lifts Price Target on Onyx Pharmaceuticals (ONXX) On Bayer Rego Settlement
-
Canaccord Genuity Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); Settlement with Bayer Removes Big Overhang
-
Baird Maintains an 'Outperform' on Onyx Pharmaceuticals (ONXX); Hitting Pay Dirt on Bayer Settlement and Nexavar Restructuring
Back to ONXX Stock Lookup
